knowledge -WSS

knowledge

author：Wikipedia 2025-09-28 02:28:53 - browse：8

intarcia implant. -- health tech coverage from STAT — The matchstick-sized, implantable device from Intarcia Therapeutics releases a steady, continuous, and low-dose stream of a drug for diabetes. Stuart Isett/Fortune Brainstorm Health

An advisory panel to the Food and Drug Administration unanimously voted against a diabetes implant from Intarcia Therapeutics — a former biotech unicorn that faltered after the FDA rejected said implant not once, but twice.

Intarcia called for the panel meeting because of those two rejections, seeking outside input on the FDA’s decision. FDA then granted Intarcia’s request. The agency is not bound to advisory panel decisions, though it tends to follow their advice.

Intarcia started developing its lead therapy, a small, skinny bar implanted under the skin, for type 2 diabetes patients in 2016. The implant delivers a glucose-controlling medicine called exenatide, a member of the GLP-1 drugs that have taken the diabetes and obesity markets by storm. Intarcia’s implant continuously administers the drug over six months, with the goal of improving patient adherence compared to Eli Lilly and Novo Nordisk’s weekly GLP-1 shots.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： FDA clears Verve to begin U.S. study of gene

WSS

How medical schools plan to diversify without affirmative action

STAT Summit: The economic case for universal basic health care

Generate Biomedicines machine learning biotech raises $273M

Health tech investors get more selective as pandemic boom fades

Food makers tried to stack nutrition panel with preferred experts

FDA clears Verve to begin U.S. study of gene

Wikipedia

knowledge

hotspot

Psychedelics group wrestles with new pharma identity

FDA proposes changes to key medical devices approval pathway

Moonlake's readout produced a cash windfall. Risks remain

Roivant's CEO is a star, but biotech's black hole persists

Virginia high school admissions case could be legal follow

What to make of Biden’s latest efforts on cancer research

Novavax promises a turnaround & Lilly roils the obesity market

The future of Biogen: Pragmatism, ‘moonshots,’ and no Twinkies

Tori Bowie and the unacceptable rates of Black maternal death

Results on Novartis prostate cancer therapy could expand its use

explore

FDA panel endorses Alnylam’s heart drug — after picking it apart

Long Covid needs a new name — and a new frame

Regeneron agrees to White House price limits on anti

Merck, Daiichi strike cancer drug pact worth up to $22 billion

White House touts steps to stem shortages of cancer treatments

STAT Summit: The economic case for universal basic health care

Wikipedia

hotspot

leisure time

focus